T Regulatory Cell Targeting for Inflammatory Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for inflammatory and neuroinflammatory diseases lack precision and safety, often causing adverse effects due to non-specific targeting and potential de-differentiation of regulatory T cells into pro-inflammatory cell types, leading to inadequate treatment of severe inflammatory conditions.
Innovation Solution
A dual-activation checkpoint system that employs a targeting mechanism with a transgenic T regulatory cell expressing a tissue-specific marker and an effector polypeptide linked to a transcription factor promoting a regulatory T cell phenotype, ensuring anti-inflammatory activity is restricted to inflamed tissues and maintaining a stable anti-inflammatory phenotype.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic or local delivery of anti-inflammatory drugs is used to treat inflammatory conditions, then acute inflammation can be treated, but longer term and more severe inflammatory conditions are not effectively treated and unwanted side effects occur
Solution Approach 1:
The patent applies local quality by engineering T regulatory cells to express tissue-specific transgenic receptors that direct the cells to specific inflamed tissues (such as CNS, lungs, or liver) rather than treating the entire body systemically. This localized targeting delivers anti-inflammatory effects precisely where needed while sparing healthy tissues from immunosuppressive side effects
Solution Approach 2:
The patent uses T regulatory cells as intermediary carriers that mediate the delivery of anti-inflammatory activity to target tissues. These engineered cells act as living intermediaries that can home to inflamed tissues and provide sustained immunosuppression locally, bridging the gap between systemic administration and localized effect
2Reliability
If T reg cells are used in anti-inflammatory therapies to suppress immune activity, then inflammation-mediated disorders can be treated, but the cells can de-differentiate into pro-inflammatory cell types and attack vulnerable tissue
Solution Approach 1:
The patent implements feedback control by engineering T reg cells with transcription factors (such as FoxP3) that are constitutively expressed to maintain regulatory phenotype. The cells also express tissue-specific transgenic receptors that provide feedback signaling to sustain FoxP3 expression and prevent de-differentiation into pro-inflammatory phenotypes when the cells encounter target tissues
Solution Approach 2:
The patent applies preliminary action by pre-engineering T reg cells with stable regulatory phenotype maintenance mechanisms before administration. The cells are pre-loaded with transcription factors and regulatory elements that proactively prevent de-differentiation before it can occur, ensuring they maintain their anti-inflammatory function throughout therapy
3Productivity
If current pharmacological immunosuppressive therapies are used to treat severe inflammatory conditions, then some symptom relief can be achieved, but the drugs lack precision and are not sufficiently potent at safe doses
Solution Approach 1:
The patent achieves high treatment potency with improved safety by localizing immunosuppressive activity to specific inflamed tissues through tissue-specific targeting receptors on T reg cells. This allows potent suppression of inflammation at the target site while maintaining normal immune function in healthy tissues, effectively increasing the therapeutic window
Data Source
AI summary
The invention relates to a nucleic acid encoding, an artificial T cell receptor, or a fragment of an artificial T cell receptor, wherein the nucleic acid is operatively linked to a transcriptional regulatory sequence, and wherein the transcriptional regulatory sequence comprises a binding domain for a transcription factor that promotes a regulatory T lymphocyte phenotype and cells comprising such nucleic acids. The cells may further comprise a nucleic acid encoding the transcription factor and a targeting polypeptide. The cells of the invention are useful in medicine, in particular in the treatment of inflammatory conditions.